Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Uptake of DPYD and UGT1A1 testing in Italy and adherence to pharmacogenetic guidelines: A 5-year perspective from an EQA provider.

British journal of clinical pharmacology - 1 Feb 2026

Roncato Rossana, Perfler Samantha, Pasin Diletta, Peruzzi Elena, Woodcock Michael, Thomas Henry, Goodall Rebecca, Patton Simon J, Cecchin Erika

Abstract excerpt

AIMS: Pharmacogenetic implementation requires awareness of the state-of-the-art practice of laboratories providing pharmacogenetic testing. This study investigated how pharmacogenetic guidelines and recommendations have been implemented over time by Italian laboratories participating in the external quality assessment (EQA) Pharmaco-scheme established since 2019 by the European Molecular genetics Quality Network...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Dihydrouracil Dehydrogenase (NADP)
Share to Glucuronosyltransferase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Guideline Adherence

Share to Irinotecan

Share to Pharmacogenetics

Share to Pharmacogenomic Testing

Share to Practice Guidelines as Topic

Share to Quality Assurance, Health Care

Source

Open in PubMed Open full text

Identifiers

PMID: 40905546
DOI: 10.1002/bcp.70247
PMCID: PMC12850544

Genes

DPYD
UGT1A1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Uptake of DPYD and UGT1A1 testing in Italy and adherence to pharmacogenetic guidelines: A 5-year perspective from an EQA provider.PMID 40905546Read ↗

Ten-year experience with pharmacogenetic testing for DPYD in a national cancer center in Italy: Lessons learned on the path to implementationSemantic proximity Read ↗

Pharmacogenetics in Italy: current landscape and future prospects.Semantic proximity Read ↗

Advancing pharmacogenetic testing in a tertiary hospital: a retrospective analysis after 10 years of activitySemantic proximity Read ↗

Real‐world implementation of DPYD and UGT1A1 pharmacogenetic testing in a community‐based cancer centerSemantic proximity Read ↗

Comparison of the Guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working GroupSemantic proximity Read ↗

Implementation of pharmacogenomics: Where are we now?Semantic proximity Read ↗

A Guide for Implementing DPYD Genotyping for Systemic Fluoropyrimidines into Clinical PracticeSemantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update.Semantic proximity Read ↗

Clinical Implementation of DPYD Pharmacogenetic Testing to Prevent Early-Onset Fluoropyrimidine-Related Toxicity in Cancer Patients in SwitzerlandSemantic proximity Read ↗

DPYD Genotyping of Patients with Fluoropyrimidine Treatment: Results of Protocol Implementation and Outcomes of Patients Carrying Unusual DPYD Variants.Semantic proximity Read ↗

Genotyping of DPYD and UGT1A1 in Brazilian oncological patients: applying pharmacogenomics in an admixed population.Semantic proximity Read ↗

Implementation of pre‐emptive testing of a pharmacogenomic panel in clinical practice: Where do we stand?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.